While the OPTIMAAL (Optimal Trial in Myocardial Infarction with the Angiotensin II Antagonist Losartan) trial could not prove either ‘superiority’ or ‘non-inferiority’ of ARBs relative to ACEi16, a more recent study showed that the use of ARBs lowered the rates of cardiovascular events compared to ACEi17. Here, AGT is linked to myocardial infarction.